Based on preclinical data showing MYC downregulation, a couple of clinical studies were started to evaluate the efficacy of ixazomib in lymphoma patients with different subtypes (DLBCL, FL, MZL, MCL, transformed FL, DLBCL-FL, and some other indolent forms) in combination with immune- or immunochemotherapy. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.